This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.
The total number entries retrieved from this search are 452| Biomarker ID | Biomarker | Biomolecule | Subject | Regulation | Biomarker's type | Experiment | Level of significance | Source | PMID |
|---|---|---|---|---|---|---|---|---|---|
| 2543 | TACSTD1, MYH4, PSPHL, CXCR4, N33, GMNN, MGP, RGS2, G1P2, AREG, EMP1, IFIT1, SPINK1, ADAMTS1, SLC2A3, EPHA3, GJA1, RDC1, KCNJ16, MX1, KRT23, THBD, MTHFD2, IFI44, IGF1, SGCE, SPARCL1, CYP3A5, ATP8B1 | RNAs | Human | Downregulated in late cirrhosis than early cirrhosis (with more than 3 fold) | Prognostic | Early v/s Late HCV Cirrhosis | p < 0.05 | Tissue | 15108252 |
| 2544 | SQLE, KIAA1919, ALDH4A1, NKTR, DICER1, C1QB, CYP2A6, EIF1AY, LPA, AKR1C4, GNMT, HLA-DRB4, IGFBP2, GPR88, MBD4, DEFA1, MADH1, HFR4, KIAA1847, FTHFD, SAA1, ASS, CRP, APOF, DBY, ATF5, RPS4Y, SAA2 | RNAs | Human | Upregulated in late cirrhosis than early cirrhosis (with more than 3 fold) | Prognostic | Early v/s Late HCV Cirrhosis | p < 0.05 | Tissue | 15108252 |
| 2545 | CDC42EP 4, IVNS1AB P, QTRT1, A2BP1, EDF1, ANXA2P3, ZNF706, STAT6, CDKN1C, DUSP6, PLOD1, ATP2A3, FAM65A, SIPA1, NCK2 | RNAs | Human | Downregulated in HCV-Cirrhosis with HCC than HCV-cirrhosis only (with fold change more than 1.3) | Prognostic | HCV-Cirrhosis v/s HCV-Cirrhosis with HCC | p < 0.05 | Tissue | 19098997 |
| 2546 | HLA-DR | Protein and RNAs | Human | Downregulated in HCC with early IHR vs. HCC without recurrence (with Fiser ratio 1.56) | Prognostic | Intrahepatic recurrence v/s Non-recurrence | p < 0.05 | Tissue | 15688398 |
| 2547 | FBN1, MEF2C, TNFAIP3, LAPTM5, TMSB4X, CUGBP2, HLA-DRA, REL, clone110298, LTBP2, TRIM22, HLA-DRBI, FOXF1, HLA-DQA, SDF1, DDX17, SGK, PDGFRA, F2R, HLADG, MTAP44, CTSK, VIM, ACVR1, ON/SPARC, SCYA3, ARHGEF6, CCND2, COL1A1, ITGB2/CD18, PTPRC, MKNK1, JUNB, EST, GATA6, FUT3, RDBP, E48, SEMA3F, COL6A3, GBAP | RNAs | Human | 11 genes (FUT3, RDBP, E48, SEMA3F, COL6A3, GBAP, FUT1, GCHFR, CYP2A, MLH1, EST) Upregulated and rest 35 genes downregulated in HCC with early IHR vs. HCC without recurrence | Prognostic | Intrahepatic recurrence v/s Non-recurrence | p < 0.05 | Tissue | 15688398 |
| 2548 | PCNA | Protein | Human | Upregulated in HCC than non-HCC (avg ratio HCC to non-tumor 9.1 +/- 5.4) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 15759316 |
| 2549 | Stathmin 1 | Protein | Human | Upregulated in HCC than non-HCC (avg ratio HCC to non-tumor 11.1 +/- 15.7) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 15759316 |
| 2550 | FGG | Protein | Human | Upregulated in well-differentiated HCC (with 2 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 15852300 |
| 2551 | Isocitrate dehydrogenase [NADP] (cytoplasmic), Fumarate hydratase (mitochondrial), Enoyl-CoA hydratase (mitochondrial), Betaine-homocysteine S-methyltransferase, Serotransferrin precursor | Protein | Human | Downregulated in well-differentiated HCC (with 2 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 15852300 |
| 2552 | Aldo-keto reductase family 1 member B10, Alpha-1-antitrypsin precursor | Protein | Human | Upregulated in poorly-differentiated HCC (with 2 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 15852300 |
| 2553 | Keratin type I cytoskeletal 10, Catalase, Aldehyde dehydrogenase (mitochondrial), GlutathioneS-transferase A1, Antioxidant protein 2, Isocitrate dehydrogenase [NADP] (cytoplasmic), Formiminotransferase-cyclodeaminase, Carbonic anhydrase I, Fructose bisphosphate aldolase B, Arginase 1, Fructose-1, 6- | Protein | Human | Downregulated in poorly-differentiated HCC (with 2 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 15852300 |
| 2554 | sterol-C5-desaturase, Peroxisomal phytanoyl-CoA alpha-hydroxylase, Homo sapiens clone 23915, Osteopontin 5/6 0, Full-length cDNA clone ZD66D02, Senescence-associated epithelial membrane protein(SEMP1), Human DNA topoisomerase II (top2) mRNA, Homo sapiens lysosomal membrane glycoprotein-2 (LAMP2), Hu | RNAs | Human | Upregulated in HCC than non-tumor | Diagnostic | Tumor v/s normal | NA | Tissue | 12136251 |
| 2555 | KIAA0959 protein, thymosin beta 4 Y isoform(TB4Y)mRNA, Pig7 (PIG7) mRNA, Fas binding protein (hDaxx), putative lung tumor suppressor(DAL1) mRNA complete cds, novel chemokine family member with altered, mRNA for Src-like adapter protein, OSF-1, Hu lambda-17 lambda-like protein (IGLL2), helix-loop-hel | RNAs | Human | Downregulated in HCC than non-tumor | Diagnostic | Tumor v/s normal | NA | Tissue | 12136251 |
| 2556 | VAMP2, ALDH3A2, DPP4, CCL3, HAPLN1, MAN2B1, RBPMS, ACSL6, ITPR2, PLEKHM2, RNF115, CIC, CALR, CENPN | RNAs | Human | Differentially expressed gene | Prognostic | cirrhotic liver tissues with and without hepatocellular carcinoma; can predict prognosis of HCC | p < 0.01 | Tissue | 19861515 |
| 2557 | DPP4, CALR | RNAs | Human | Differentially expressed gene | Prognostic | cirrhotic liver tissues with and without hepatocellular carcinoma; can predict prognosis of HCC | p < 0.01 | Tissue | 19861515 |
| 2558 | DPP4, VAMP2, EGR1 | RNAs | Human | Differentially expressed gene | Prognostic | cirrhotic liver tissues with and without hepatocellular carcinoma; can predict prognosis of HCC | p < 0.01 | Tissue | 19861515 |
| 2559 | IL1A,IL1B,IL2,IL12A,IL12B,IL15,IFNG,TNF,IL4,IL5,IL8,IL10,CSF1,ANXA1,HLA-DRA,HLA-DPA1,PRG1 | RNAs | Human | Diffrentially expressed between MIM (metastasis-inclined microenvironment) v/s MAM (metastasis-averse microenvironment ) | Prognostic | MIM (metastasis-inclined microenvironment) v/s MAM (metastasis-averse microenvironment ) | p < 0.05 | Tissue | 16904609 |
| 2560 | IL1A,IL1B,IL2,IL12A,IL12B,IL15,IFNG,TNF,IL4,IL5,IL8,IL10,CSF1,ANXA1,HLA-DRA,HLA-DPA1,PRG1 | RNAs | Human | Diffrentially expressed between MIM (metastasis-inclined microenvironment) v/s MAM (metastasis-averse microenvironment ) | Prognostic | Recurrence v/s non-recurrence | p < 0.05 | Tissue | 16904609 |
| 2561 | HSP70 | Protein | Human | Upregulated in early HCC components | Diagnostic and prognostic | nodule-in-nodule-type HCCs and corresponding noncancerous liver tissues | p< .001 | Tissue | 12500205 |
| 2562 | galectin-3,serine/threonine kinase, translation factor eIF- 4A, -4B, -3, fibroblast growth factor receptor, and ri- bosomal protein L35A | RNAs | Human | Upregulated in HCC | Diagnostic | HCC v/s non-tumor | Tissue | 12521301 | |
| 2563 | Nip3, decorin, and the insulin-like growth factor binding protein-3 | RNAs | Human | Downregulated in HCC | Diagnostic | HCC v/s non-tumor | Tissue | 12521301 | |
| 2564 | EFNA1 | Protein and RNAs | Human | Upregulated in HCC | Diagnostic and Prognostic | HCC v/s non-tumor/normal; associated with the poor survival of patients | p< 0.001 | Tissue and Seum | 19642143 |
| 2565 | EphA2 | Protein and RNAs | Human | Downregulated in HCC | Diagnostic and Prognostic | HCC v/s non-tumor/normal; associated with the poor survival of patients | p < 0.05 | Tissue and Seum | 19642143 |
| 2566 | Matrixmetalloproteinase14 or MMP14, MT-MMP1,osteonectin/SPARC | RNAs | Human | Upregulated in all three tested HCC samples. | Diagnostic | HCC v/s non-tumor | p < 0.05 | Tissue | 11813304 |
| 2567 | Cu/Zn-SOD | RNAs | Human | Downregulated in all three tested HCC samples. | Diagnostic | HCC v/s non-tumor | p < 0.07 | Tissue | 11813304 |
| 2568 | VIM or Vimentin | RNAs | Human | Upegulated in HCC | Prognostic | Primary v/s metastasis; significantly associated with HCC metastasis | p< 0.01 | Tissue | 14647434 |
| 2569 | H19 and IGF2 | RNAs | Human | Upregulated in B-type HCC | Diagnostic | HBV-HCC vs HCV -HCC; associated with the progression of HCC | p < 0.05 | Tissue | 12124323 |
| 2570 | MAP2K4, MAP2K5, SF1, SIAHBP1, and MYOG | RNAs | Human | Upregulated in B-type HCC | Diagnostic | HBV-HCC vs HCV -HCC; associated with the progression of HCC | P< 0.05 | Tissue | 12124323 |
| 2571 | MMP9 and VEGF | RNAs | Human | Upregulated in B-type HCC | Diagnostic | HBV-HCC vs HCV -HCC; associated with the progression of HCC | P< 0.05 | Tissue | 12124323 |
| 2572 | MT1E, MT1H, ADH1B, ADH4, CYP2A7, andCYPIIE | RNAs | Human | Upregulated in C-type HCC | Diagnostic | HBV-HCC vs HCV -HCC; associated with the progression of HCC | P< 0.05 | Tissue | 12124323 |
| 2573 | BMP4, FLNB, GNG11, GFR, and PTPRK | RNAs | Human | Upregulated in HBV-HCCs from patients with LC | Diagnostic | HBV-HCCs patients with LC (liver cirrhosis) vs without LC (liver cirrhosis) | P< 0.05 | Tissue | 12771952 |
| 2574 | NFIB,GFI1,TAF1,ONECUT1,BTF,andTRIM32 | RNAs | Human | Upregulated in HBV-HCCs from patients with LC | Diagnostic | HBV-HCCs patients with LC (liver cirrhosis) vs without LC (liver cirrhosis) | P< 0.05 | Tissue | 12771952 |
| 2575 | APOC1, APOC2, andAPOC3 | RNAs | Human | Upregulated in HBV-HCCs from patients with LC | Diagnostic | HBV-HCCs patients with LC (liver cirrhosis) vs without LC (liver cirrhosis) | P< 0.05 | Tissue | 12771952 |
| 2576 | IGF2 | RNAs | Human | Upregulated in HBV-HCCs from patients with LC | Diagnostic | HBV-HCCs patients with LC (liver cirrhosis) vs without LC (liver cirrhosis) | P< 0.05 | Tissue | 12771952 |
| 2577 | PHB | RNAs | Human | Downregulated in HBV-HCCs from patients with LC | Diagnostic | HBV-HCCs patients with LC (liver cirrhosis) vs without LC (liver cirrhosis) | P< 0.05 | Tissue | 12771952 |
| 2578 | IGFBP3 | RNAs | Human | Downregulated in HBV-HCCs from patients with LC | Diagnostic | HBV-HCCs patients with LC (liver cirrhosis) vs without LC (liver cirrhosis) | P< 0.05 | Tissue | 12771952 |
| 2579 | HSPA1B | RNAs | Human | Downregulated in HBV-HCCs from patients with LC than HBV-HCCs without LC | Diagnostic | HBV-HCCs patients with LC (liver cirrhosis) vs without LC (liver cirrhosis) | P< 0.05 | Tissue | 12771952 |
| 2580 | Dystrophin, Homolog to tubulin beta chain, Zinc finger protein 337, Friedreich ataxia region gene X123, Fibronectin (Alt. Splice 1), Zinc finger protein 9, Metallothionein IV, Poly(rC) binding protein 3, KIAA0426 gene product, Hypothetical protein FLJ13910, RAN binding protein 2 like 1, S100 calcium | RNAs | Human | Downregulated in L1 than L0 (with fisher ratio more than 9.74) | Prognostic | non-tumorous livers L1 (with HCV infection) v/s and L0 (without HCV infection) ; associated with invasion or metastsis | P = 0.001 | Tissue | 15710396 |
| 2581 | Cystatin C, Prolylcarboxypeptidase (angiotensinase C), Lysyl-tRNA synthetase, Voltage-dependent anion channel 3, Protective protein for beta-galactosidase (cathepsin A), Interferon gamma-inducible protein 30, Signal sequence receptor delta, Thioredoxin-related transmembrane protein, Cathepsin D, Ras | RNAs | Human | Upregulated in L1 than L0 (with Fisher ratio more than 8.9) | Prognostic | non-tumorous livers L1 (with HCV infection) v/s and L0 (without HCV infection) ; associated with invasion or metastsis | P = 0.001 | Tissue | 15710396 |
| 2582 | Mannose receptor C type 1, BCL2/adenovirus E1B 19 kD interacting protein 3 like, v-fos FBJ murine osteosarcoma viral oncogene homolog, Ficolin 3 (Hakata antigen), Calmodulin 1, v-maf musculoaponeurotic fibrosarcoma oncogene homolog, Metallothionein 1H, Metallothionein 1E, Solute carrier family 31 me | RNAs | Human | Downregulated in G1 than L1 (with fisher ratio more than 9) | Prognostic | non-tumorous livers L1 (with HCV infection) v/s G1 (well differentiated) HCV-HCC; associated with invasion or metastsis | P = 0.001 | Tissue | 15710396 |
| 2583 | SNRPB, TBCE, DRAP1, UFD1L, MT4, ATP6V1E, calmodulin dependent protein kinase 2, ZFP103, ATOX1, Interleukin enhancer binding factor 2 | RNAs | Human | Upregulated in G1 than L1 (with fisher ratio more than 9) | Prognostic | non-tumorous livers L1 (with HCV infection) v/s G1 (well differentiated) HCV-HCC; associated with invasion or metastsis | P = 0.001 | Tissue | 15710396 |
| 2584 | OAS2, ADH1A, FLJ20378, HSF2, PSME1, E2L6, UBE2L6, STAT1, LIM, FLN29, GABARAPL1, | RNAs | Human | Downregulated in G2 than G1 (with fisher ratio more than 1.7) | Prognostic | G1 (well differentiated) HCV-HCC v/s G2 (moderately differentiated) HCV-HCC; associated with invasion or metastsis | P < 0.005 | Tissue | 15710396 |
| 2585 | RPNI, ZNF161, EIF4G1, FNBP3, CCT6A, PPIB, IMPA2, GORASP2, KIAA0669, ATP2A2, PA200, ZNF91, GOLGA4, KIAA0494, SIAH1, UBQLN2, ADNP, TPD52L2, FDPS, DICER1 | RNAs | Human | Upregulated in G2 than G1 (with fisher ratio more than 1.7) | Prognostic | G1 (well differentiated) HCV-HCC v/s G2 (moderately differentiated) HCV-HCC; associated with invasion or metastsis | P < 0.005 | Tissue | 15710396 |
| 2586 | APOC1, SEPP1, PDZGEF1, SCML2, ALDH5A1, BNIP3, FBXW1B, PAH, Homo sapiens clone 24473 mRNA sequence, PACE4, FLJ31305 fis or clone LIVER1000104 or , Unknown or , MIG2, RARRES2, BAAT, KDELR2, RNP24, FACL2, KIAA0977 protein, HADHSC, HADHSC, SDHD, CPB2, PGRMC1, AOP2, PPM1A, SDC1, CCL14, EST | RNAs | Human | Downregulated in G3 compared with G2 (with Fisher ratio more than 1.3) | Prognostic | G2 (moderately differentiated) HCV-HCC v/s G2 (poorly differentiated) HCV-HCC; associated with invasion or metastsis | P < 0.005 | Tissue | 15710396 |
| 2587 | DAZAP2, SPINT1, LGALS9, CYBA, BAZ2A, PPT1, S100A13, LGALS9, PIM2, TGFB1 | RNAs | Human | Upregulated in G3 compared with G2 (with Fisher ratio more than 1.3) | Prognostic | G2 (moderately differentiated) HCV-HCC v/s G2 (poorly differentiated) HCV-HCC; associated with invasion or metastsis | P < 0.005 | Tissue | 15710396 |
| 2588 | NM23-H2,MCM7, PARP1, YWHAH, HSPB1, MSH2 | RNAs | Human | Upregulated in tumor | Diagnostic | HCC v/s non-tumor | P<0.001 | Tissue | 16703398 |
| 2589 | MT1A, MT3 | RNAs | Human | downregulated in tumor | Diagnostic | HCC v/s non-tumor | P<0.001 | Tissue | 16703398 |
| 2590 | MPV17, EST, GZMB, ITGA6, EST, CENPC1, EST, SPP1, RTF1, CYB5-M, P4HA2, DNMBP, EST, DNAJB4, PRH1, STK23, TCF2, POSTN, SPP1, WIZ, OSMR, EST, ILIA, CD44, EST, MUC6, MTHFD2, ANXA2, PCSK2, RBP1, EST, ITGA6, APRT, PDUM3, TPM2, RNASE3, OSMR, GRK1, SLC14A, FETUB, ANXA2P1, UGT2B15, EST, KIAA0703, AKAP10, AVPR | RNAs | Human | Genes associated with EHR of HCC | Prognostic | Extrahepatic recurrence (EHR) v/s Early intrahepatic recurrence (IHR) | P< 0.05 | Tissue | 17016605 |
| 2591 | ITGA6, SPP1, DNMBP, CD44, POSTN | RNAs | Human | Upregulated in HCC with EHR than in HCC without EHR. | Prognostic | HCC with EHR (Extrahepatic recurrence) v/s HCC without EHR. | P< 0.05 | Tissue | 17016605 |
| 2592 | ITGA6, SPP1 | RNAs | Human | Upregulated in HCC with EHR than HCC without EHR and non-cancerous liver tissue ( also higher expression in HCC without EHR than non-cancerous liver tissue) | Prognostic | HCC with EHR (Extrahepatic recurrence) v/s HCC without EHR. | P< 0.05 | Tissue | 17016605 |